Weekly Digest – Feb 2024 Weekly Digest – Feb 2024 15 Feb 2024: Ministry of Health, Japan, grants priority review for PADCEV and KEYTRUD combination in first-line advanced bladder cancer treatment Astellas Pharma Inc. announced that Japan’s Ministry of Health, […]
Weekly Digest – Feb 2024 Weekly Digest – Feb 2024 15 Feb 2024: Lantern Pharma progresses novel ADC program in various solid tumors Lantern has advanced the development, synthesis, and preclinical POC of a novel, highly potent, cryptophycin-based ADC The […]
Weekly Digest – Feb 2024 Weekly Digest – Feb 2024 15 Feb 2024: Dragonfly and Gilead to Explore DF1001 HER-2 TriNKET with Trodelvy in Cancer Dragonfly Therapeutics has initiated a clinical collaboration to assess DF1001, a HER-2 immune engager developed […]
Weekly Digest – Feb 2024 Weekly Digest – Feb 2024 12 Feb 2024: AbbVie acquires ImmunoGen, including flagship ADC Elahere AbbVie finalized its acquisition of ImmunoGen, which bolsters the company’s pipeline of antibody-drug conjugates (ADCs) AbbVie gains ImmunoGen’s flagship ADC […]
